Aleksandr Ianevski

ORCID: 0000-0002-7780-482X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Computational Drug Discovery Methods
  • Influenza Virus Research Studies
  • interferon and immune responses
  • SARS-CoV-2 and COVID-19 Research
  • Acute Myeloid Leukemia Research
  • Respiratory viral infections research
  • Protein Degradation and Inhibitors
  • COVID-19 Clinical Research Studies
  • Chronic Lymphocytic Leukemia Research
  • Viral Infections and Immunology Research
  • Immune Cell Function and Interaction
  • Chronic Myeloid Leukemia Treatments
  • Single-cell and spatial transcriptomics
  • Cancer Genomics and Diagnostics
  • CAR-T cell therapy research
  • Hepatitis C virus research
  • CRISPR and Genetic Engineering
  • Bioinformatics and Genomic Networks
  • Viral gastroenteritis research and epidemiology
  • Statistical Methods in Clinical Trials
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • vaccines and immunoinformatics approaches
  • Mosquito-borne diseases and control
  • Digital Imaging for Blood Diseases
  • Viral Infections and Outbreaks Research

Norwegian University of Science and Technology
2018-2025

Institute for Molecular Medicine Finland
2017-2025

University of Helsinki
2017-2025

Helsinki University Hospital
2024

University Medical Center
2024

University Hospital Leipzig
2024

Charité - Universitätsmedizin Berlin
2024

University Hospital Cologne
2024

Finland University
2018-2022

Helsinki Institute for Information Technology
2018-2022

Abstract SynergyFinder (https://synergyfinder.fimm.fi) is a stand-alone web-application for interactive analysis and visualization of drug combination screening data. Since its first release in 2017, has become widely used web-tool both the discovery novel synergistic combinations pre-clinical model systems (e.g. cell lines or primary patient-derived cells), better understanding mechanisms treatment efficacy resistance. Here, we describe latest version (release 2.0), which extensively been...

10.1093/nar/gkaa216 article EN cc-by Nucleic Acids Research 2020-03-25

Rational design of drug combinations has become a promising strategy to tackle the sensitivity and resistance problem in cancer treatment. To systematically evaluate pre-clinical significance pairwise combinations, functional screening assays that probe combination effects dose-response matrix assay are commonly used. facilitate analysis such experiments, we implemented web application uses key functions R-package SynergyFinder, provides not only flexibility using multiple synergy scoring...

10.1093/bioinformatics/btx162 article EN cc-by-nc Bioinformatics 2017-03-21

Abstract Identification of cell populations often relies on manual annotation clusters using established marker genes. However, the selection genes is a time-consuming process that may lead to sub-optimal annotations as markers must be informative both individual and various types present in sample. Here, we developed computational platform, ScType, which enables fully-automated ultra-fast cell-type identification based solely given scRNA-seq data, along with comprehensive database...

10.1038/s41467-022-28803-w article EN cc-by Nature Communications 2022-03-10

SynergyFinder (https://synergyfinder.fimm.fi) is a free web-application for interactive analysis and visualization of multi-drug combination response data. Since its first release in 2017, has become popular tool multi-dose data analytics, partly because the development functionality graphical interface been driven by diverse user community, including both chemical biologists computational scientists. Here, we describe latest upgrade this community-effort, 3.0, introducing number novel...

10.1093/nar/gkac382 article EN cc-by Nucleic Acids Research 2022-04-29

As of June 2020, the number people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, more than 6.7 million cases worldwide. Both World Health Organization (WHO) and United Nations (UN) has highlighted need for better control SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies antiviral drugs against can be time-consuming costly. Convalescent sera safe-in-man broad-spectrum antivirals (BSAAs) are readily...

10.3390/v12060642 article EN cc-by Viruses 2020-06-13

With the increasing pace of global warming, it is important to understand role meteorological factors in influenza virus (IV) epidemics. In this study, we investigated impact temperature, UV index, humidity, wind speed, atmospheric pressure, and precipitation on IV activity Norway, Sweden, Finland, Estonia, Latvia Lithuania during 2010–2018. Both correlation machine learning analyses revealed that low temperature indexes were most predictive for epidemics Northern Europe. Our vitro...

10.3390/v11030207 article EN cc-by Viruses 2019-03-01

High-throughput screening (HTS) enables systematic testing of thousands chemical compounds for potential use as investigational and therapeutic agents. HTS experiments are often conducted in multi-well plates that inherently bear technical experimental sources error. Thus, data processing requires the robust quality control procedures before analysis interpretation. Here, we have implemented an open-source application, Breeze, integrated application data. Furthermore, Breeze a reliable way...

10.1093/bioinformatics/btaa138 article EN cc-by-nc Bioinformatics 2020-02-26

Viruses are the major causes of acute and chronic infectious diseases in world. According to World Health Organization, there is an urgent need for better control viral diseases. Repurposing existing antiviral agents from one disease another could play a pivotal role this process. Here, we identified novel activities obatoclax emetine against herpes simplex virus type 2 (HSV-2), echovirus 1 (EV1), human metapneumovirus (HMPV) Rift Valley fever (RVFV) cell cultures. Moreover, demonstrated...

10.3390/v11100964 article EN cc-by Viruses 2019-10-18

Viruses are one of the major causes acute and chronic infectious diseases thus a contributor to global burden disease. Several studies have shown how viruses evolved hijack basic cellular pathways evade innate immune response by modulating key host factors signalling pathways. A collective view these multiple could advance our understanding virus-host interactions provide new therapeutic perspectives for treatment viral diseases. Here, we performed an integrative meta-analysis elucidate 17...

10.3389/fimmu.2019.02186 article EN cc-by Frontiers in Immunology 2019-10-04

Therapeutic options for coronaviruses remain limited. To address this unmet medical need, we screened 5406 compounds, including United States Food and Drug Administration (FDA)-approved drugs bioactives, activity against a South Korean Middle East respiratory syndrome coronavirus (MERS-CoV) clinical isolate. Among 221 identified hits, 54 had therapeutic indexes (TI) greater than 6, representing effective drugs. The time-of-addition studies with selected demonstrated eight four FDA-approved...

10.3390/v13040651 article EN cc-by Viruses 2021-04-09

Enteroviruses are a significant global health concern, causing spectrum of diseases from the common cold to more severe conditions like hand-foot-and-mouth disease, meningitis, myocarditis, pancreatitis, and poliomyelitis. Current treatment options for these infections limited, underscoring urgent need effective therapeutic strategies. To find better option we analyzed efficacy 12 known broad-spectrum anti-enterovirals both individually in combinations against different enteroviruses vitro....

10.1016/j.antiviral.2024.105842 article EN cc-by Antiviral Research 2024-02-26

Combination therapies have become a standard for the treatment HIV and hepatitis C virus (HCV) infections. They are advantageous over monotherapies due to better efficacy, reduced toxicity, as well ability prevent development of resistant viral strains treat co-infections. Here, we identify new synergistic combinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), echovirus 1 (EV1), human immunodeficiency (HIV-1) in vitro. We observed activity nelfinavir with...

10.3390/v12101178 article EN cc-by Viruses 2020-10-18

Drug combinations are becoming a standard treatment of many complex diseases due to their capability overcome resistance monotherapy. In the current preclinical drug combination screening, top for further study often selected based on synergy alone, without considering efficacy and toxicity effects, even though these critical determinants clinical success therapy. To promote prioritization integrated analysis synergy, profiles, we implemented web-based open-source tool, SynToxProfiler...

10.1371/journal.pcbi.1007604 article EN cc-by PLoS Computational Biology 2020-02-03

In myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN), bone marrow (BM) histopathology is assessed to identify dysplastic cellular morphology, cellularity, blast excess. Yet, other morphologic findings may elude the human eye. We used convolutional neural networks extract features from 236 MDS, 87 MDS/MPN, 11 control BM biopsies. These predicted genetic cytogenetic aberrations, prognosis, age, gender in multivariate regression models. Highest prediction accuracy was found...

10.1158/2643-3230.bcd-20-0162 article EN Blood Cancer Discovery 2021-03-22

Abstract Greater nitrogen efficiency would substantially reduce the economic, energy and environmental costs of rice production. We hypothesized that synergistic balancing benefits for soil exploration among root architectural phenes is beneficial under suboptimal availability. An enhanced implementation functional–structural model OpenSimRoot integrated with ORYZA_v3 crop was used to evaluate utility combinations phenes, namely nodal angle, proportion smaller diameter roots, number; L‐type...

10.1111/pce.14284 article EN cc-by Plant Cell & Environment 2022-02-10

Imagine a future viral pandemic where if you test positive for the new virus, can quickly take some medicines at home few days so that do not get too sick. To date, only single drugs have been approved outpatient use against SARS-CoV-2, and we are learning these limitations may succumb to drug resistance.

10.1128/spectrum.03331-22 article EN cc-by Microbiology Spectrum 2022-10-03
Coming Soon ...